A Phase I, Open-Label, Randomised, Single Dose, Crossover Pharmacokinetic Study Comparing a Capsule Formulation of BIT225 to the Current Oral Suspension Administered in Healthy Participants.
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
At a glance
- Drugs BIT 225 (Primary)
- Indications Hepatitis C; HIV infections
- Focus Pharmacokinetics
- 14 Aug 2013 Results published in a Biotron media release.
- 08 Aug 2013 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 04 Jun 2013 New trial record